The overall goal of the Gene and Cellular Therapy Core (CoreG) is to provide support for HIV/AIDS-related research requiring stem cells, gene delivery vectors and technical expertise for efficient genetic modification of stem cells. Recent advancements in gene delivery vector systems and stem cell technologies have enabled genetic modification of human hematopoietic stem/progenitor cells (HSPC) to resist HIV infection. The Gene and Cellular Therapy Core is established to meet the increasing demand to promote and facilitate basic and translational research in this area by providing UCLA CFAR investigators and their domestic and international collaborators with highly purified and well characterized human CD34+ HSPC, embryonic stem cells (hESC), induced pluripotent stem cells (iPSC), human fetal tissues and lentiviral vector technologies that enable efficient genetic engineering of stem cells to resist HIV infection. The Core also provides consultation for researchers with limited experience in stem cell and viral vector technologies, in particular early stage investigators. As the use of stem cells and vector technology requires specialized expertise and resources for efficient genetic engineering of different types of stem cells, offering access to these technologies can significantly facilitate and expand the scope of UCLA CFAR research activities. Our services are more cost-effective than utilizing the limited commercial sources. Further value is added by customized technical support available from accessible and knowledgeable core staffs who can work closely with investigators to troubleshoot and optimize experiments, assist with institutional regulatory compliance documents and who are actively engaged in development and application of stem cell and vector technologies. These core services will facilitate translation of stem cell and gene therapy-related HIV research into therapeutic applications.
The UCLA CFAR Gene and Cellular Therapy Core provides support for human stem cell-base3d gene therapy research. The core services and technical expertise can facilitate research efforts to make rapid progress towards providing a new therapy for HIV infected individuals to stably control HIV infection.
| Allyn, P R; O'Malley, S M; Ferguson, J et al. (2018) Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection. Int J STD AIDS 29:334-340 |
| Khamaikawin, Wannisa; Shimizu, Saki; Kamata, Masakazu et al. (2018) Modeling Anti-HIV-1 HSPC-Based Gene Therapy in Humanized Mice Previously Infected with HIV-1. Mol Ther Methods Clin Dev 9:23-32 |
| Foo, Suan-Sin; Chen, Weiqiang; Chan, Yen et al. (2018) Biomarkers and immunoprofiles associated with fetal abnormalities of ZIKV-positive pregnancies. JCI Insight 3: |
| Gorbach, Pamina M; Javanbakht, Marjan; Bolan, Robert K (2018) Behavior change following HIV diagnosis: findings from a Cohort of Los Angeles MSM. AIDS Care 30:300-304 |
| Rotheram-Borus, Mary Jane; Davis, Emily; Rezai, Roxana (2018) Stopping the rise of HIV among adolescents globally. Curr Opin Pediatr 30:131-136 |
| Allan-Blitz, Lao-Tzu; Sakona, Ashyln; Wallace, William D et al. (2018) Coxiella burnetii Endocarditis and Meningitis, California, USA, 2017. Emerg Infect Dis 24: |
| Kojima, Noah; Klausner, Jeffrey D (2018) An Update on the Global Epidemiology of Syphilis. Curr Epidemiol Rep 5:24-38 |
| Nakatsuka, Nako; Hasani-Sadrabadi, Mohammad Mahdi; Cheung, Kevin M et al. (2018) Polyserotonin Nanoparticles as Multifunctional Materials for Biomedical Applications. ACS Nano 12:4761-4774 |
| Cisneros, Irma E; Erdenizmenli, Mert; Cunningham, Kathryn A et al. (2018) Cocaine evokes a profile of oxidative stress and impacts innate antiviral response pathways in astrocytes. Neuropharmacology 135:431-443 |
| Marsden, Matthew D; Wu, Xiaomeng; Navab, Sara M et al. (2018) Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. Virology 520:83-93 |
Showing the most recent 10 out of 942 publications
